Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Uriset is an oral small molecule medication containing febuxostat, marketed by Cam Neuro Pharma for the management of chronic hyperuricemia in patients with gout. As a potent and selective non-purine xanthine oxidase inhibitor, it works by blocking the enzyme responsible for the conversion of hypoxanthine and xanthine into uric acid. By lowering serum uric acid levels, Uriset helps prevent the formation of urate crystals and reduces the frequency of gout flares. It is typically indicated for adults who have an inadequate response or intolerance to allopurinol.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Uriset.